Page 38 - Pharming Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Beam Therapeutics (NASDAQ:BEAM – Get Rating) and Orchard Therapeutics (NASDAQ:ORTX – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends. Valuation & Earnings This table compares Beam Therapeutics and Orchard […]

Pharming Group (OTCMKTS:PHGUF – Get Rating) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports. According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced […]

LEIDEN, Netherlands, May 18, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that at its Annual General Meeting of

Pharming Group (NASDAQ:PHAR – Get Rating) – Equities research analysts at Oppenheimer lifted their FY2026 EPS estimates for Pharming Group in a research report issued to clients and investors on Thursday, May 12th. Oppenheimer analyst H. Singh now expects that the company will earn $0.06 per share for the year, up from their previous estimate […]

Pharming Group (OTCMKTS:PHGUF – Get Rating) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 1,525,800 shares, a growth of 31.7% from the April 15th total of 1,158,400 shares. Based on an average daily volume of 400 shares, the days-to-cover ratio is currently […]